BENRALIZUMAB (FASENRA) prior authorization at Kaiser Permanente
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
The PA criteria you'll need to meet
Kaiser Permanente reviews BENRALIZUMAB (FASENRA) prior authorizations against its medical policy for Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]. The FDA-approved indication (2017) is INJECTABLE. Kaiser Permanente-specific context: Integrated delivery system — care + insurance coordinated. California DMHC oversight is unique. CA IMR (Independent Medical Review) is a powerful external review track for Kaiser denials.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Kaiser Permanente's medical policy URL referenced in the cover letter
Kaiser Permanente's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- Out-of-network non-emergency denials
- Specialty referrals delayed
- Mental health access (DMHC complaints common)
If the PA is denied
Kaiser Permanente gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://providers.kaiserpermanente.org) with the same packet plus a peer-reviewed citation supporting BENRALIZUMAB (FASENRA)for the patient's indication.
Contact Kaiser Permanente
- Provider portal: https://providers.kaiserpermanente.org
Frequently asked questions
What documentation does Kaiser Permanente need for BENRALIZUMAB (FASENRA) prior auth?
Kaiser Permanente's typical PA packet for BENRALIZUMAB (FASENRA): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC], expect clinical-criteria documentation specific to this class.
What's the turnaround time at Kaiser Permanente?
Standard BENRALIZUMAB (FASENRA) PA decisions at Kaiser Permanente: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Kaiser Permanente most often reject BENRALIZUMAB (FASENRA) for?
Across Kaiser Permanente's book the common rejection patterns include: Out-of-network non-emergency denials; Specialty referrals delayed; Mental health access (DMHC complaints common). For BENRALIZUMAB (FASENRA) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
How do I prep for a peer-to-peer with Kaiser Permanente on BENRALIZUMAB (FASENRA)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Generate the BENRALIZUMAB (FASENRA) PA packet
Open ApprovalHelp — generate a BENRALIZUMAB (FASENRA) prior-auth packet tailored to Kaiser Permanente's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com